CORIST topline results

Webcast at 10:00 am CET

October 4, 2022

SCANDION ONCOLOGY

Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.

This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.

The Global and European Burden of Cancer

19 million new cancer cases every year in the world

10 million deaths every year in the world

2 million deaths every year in Europe

Leading causes of cancer death



Colorectal cancer: **2nd** most common cause of **cancer death**

Pancreatic cancer: **7th** most common cause of **cancer death**

90% of cancer deaths are due to **resistance against current treatment options**

No drugs are yet available to counteract drug resistance and increase patient survival

SCANDION ONCOLOGY

Pipeline

Developing first-in-class medicines for personalized therapy targeting cancer drug resistance



SCANDION ONCOLOGY

CORIST topline results

SCANDION ONCOLOGY

CORIST Design and Endpoints

- CORIST is a phase II study, with primary endpoint overall response rate (ORR) according to RECIST 1.1
- As originally designed, it also contains a dose escalation part (part 1) to identify the most suitable dose of SCO-101 in combination with FOLFIRI chemotherapy in a schedule over 7 days. After a suitable dose was found, an expansion of 25 patients (part 2) would assess the efficacy
- Based on part 1 and part 2 pharmacokinetics and pharmacodynamics evidence, the study has been recently amended to explore the potential of a different schedule over 6 days, expected to be possibly the best way to combine SCO-101 and FOLFIRI chemotherapy (part 3 & 4)
- The new part 3 will try to escalate the dose of SCO-101 and FOLFIRI above those employed in part 2
- Part 4 will confirm in up to 24 patients the efficacy of this combination, again based on ORR. The usual secondary endpoints of PFS and OS will also be assessed

Topline Results of CORIST part 2

- The dose identified in part 1 was explored in 25 Ras WT patients, all of whom had at least a CT scan after 8 weeks of treatment as per protocol
- The feasibility and safety of combining SCO-101 and FOLFIRI in a schedule over 7 days was confirmed
- Tumor reduction has been observed in some patients, however below the +30% threshold defined as the trial's primary endpoint
- Thus, a proof of concept for efficacy was not reached as no RECIST responses were observed at the planned timepoint of 8 weeks from treatment start
- Evidence of prolonged progression free survival and stable disease (secondary endpoints) was observed in some patients

- Overall, the evidence gathered so far from part 2 of the study, including safety, preliminary activity and pharmacokinetics, support the expansion of the study to investigate a potentially improved modality for combining SCO-101 and FOLFIRI chemotherapy

Expansion of CORIST (part 3 and 4)

- The CORIST trial was expanded by adding a new schedule for combining SCO-101 and chemotherapy over 6 days, which will be evaluated in patients with both RAS wild-type (WT) and RAS mutated mCRC
- CORIST part 3 will evaluate the safety and tolerability of SCO-101 in combination with FOLFIRI when dosed according to the different schedule
- CORIST part 3 is planned to include up to 36 mCRC patients with RAS WT and RAS mutated tumors (up to 6 escalation cohorts with a 3+3 design)
- Topline results from CORIST part 3 are expected most likely within Q3, 2023

- In CORIST part 4, up to 24 mCRC patients will be enrolled to assess the preliminary activity of SCO-101 combined with FOLFIRI, administered at the optimal dose found in part 3

Next Planned Communication

- In Q1 2023 we will update on the expected timeline of part 3 completion (if based on the number of patients recruited and toxicity observed we are confident the Q3 2023 timeline can be met)
- When CORIST part 3 is completed we will inform about the dose reached with topline results about the safety and tolerability of the new schedule and any activity observed in the part 3 patients
- At this time point there will also be an update about part 2 patients, with a focus on those who are continuing treatment as of today
- Topline results of part 4 will be communicated after all patients have undergone at least the first CT scan on study at 8 weeks, similarly to present communication about part 2

- This may be in the second half of 2023 or first half of 2024, mainly depending on the number of patients recruited in part 3
- The final CORIST study results can be expected approximately 6 months later

Our vision is to overcome cancer drug resistance and improve lives for cancer patients and their families

Our aim is to make existing cancer treatments work better and longer

SCANDION ONCOLOGY